FDA Approves Asthma Indication for Dupixent® (dupilumab)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/2/2026

1. PANW
2. GTLB
3. MDB
4. DELL
5. GOOGL
6. SPY
7. USO
8. AAPL
9. MMED
10. NVDA

Go back to FDA Approves Asthma Indication for Dupixent® (dupilumab)
Regeneron (NASDAQ: REGN) Delayed: 854.30 +30.48 (3.70%)
Previous Close $823.82    52 Week High $592.36 
Open $826.24    52 Week Low $325.35 
Day High $854.49    P/E 224.23 
Day Low $825.77    EPS $3.81 
Volume 470,025